Troy’s odyssey
This article was originally published in The Tan Sheet
Executive Summary
Former FDA Chief Counsel Dan Troy and Special Assistant to the Chief Counsel Coleen Klasmeier will join Sidley Austin Brown & Wood this month, the law firm announces Jan. 6. Troy will provide "strategic counsel on FDA-related matters" and practice administrative and constitutional law with a focus on the pharma, biotech and medical device industries; he announced his departure from FDA in November (1"The Tan Sheet" Nov. 22, 2004, p. 10). Klasmeier is joining the firm's life sciences practice with a focus on the pharma, medical device and food industries...
You may also be interested in...
FDA Chief Counsel Warning Letter Review To Continue After Troy’s Departure
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said
TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens
The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.
Advisory Committee For Biogen's Aducanumab Will Test US FDA's 'Substantial Evidence' Flexibility
Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the ‘substantial evidence’ standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: